To include your compound in the COVID-19 Resource Center, submit it here.

Galapagos, MorphoSys report Phase I data for atopic dermatitis candidate

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and MorphoSys AG (Xetra:MOR; Pink:MPSYY) reported pooled data from 25 patients with moderate to severe atopic dermatitis across

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE